Issues
Cancer Research
Table of Contents
Advances in Brief
Suppression of Tumor Metastasis by Blockade of Transforming Growth Factor β Signaling in Bone Marrow Cells through a Retroviral-mediated Gene Therapy in Mice1
High-Level Expression of the Smad Ubiquitin Ligase Smurf2 Correlates with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma1
Cancer-inducible Transgene Expression by the Grp94 Promoter: Spontaneous Activation in Tumors of Various Origins and Cancer-associated Macrophages1
Biochemistry and Biophysics
Carcinogenesis
Both E7 and CpG-Oligodeoxynucleotide Are Required for Protective Immunity against Challenge with Human Papillomavirus 16 (E6/E7) Immortalized Tumor Cells: Involvement of CD4+ and CD8+ T Cells in Protection1
Epidemiology and Prevention
Experimental Therapeutics
Cancer Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-stimulating Factor-encapsulated Microspheres: Coinduction of Innate and Adaptive Antitumor Immunity and Cure of Disseminated Disease1
Reexpression of the Tumor Suppressor Gene ARHI Induces Apoptosis in Ovarian and Breast Cancer Cells through a Caspase-independent Calpain-dependent Pathway1
Molecular Biology and Genetics
Tumor Biology
Simultaneous Reduction in Cancer Pain, Bone Destruction, and Tumor Growth by Selective Inhibition of Cyclooxygenase-21
Obituary
Acknowledgment to Reviewers
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.